Goldfinch Bio, a U.S.-based, clinicaφ≥♣l stage biotechnology company focused on discov≈γ★ering and developing precis± λion medicines for the treatment of×✘÷ kidney diseases, today α↕‍announced it entered into a license​✘≠ agreement with Takeda Pharmac♦₩λ∏eutical Company Limited (“Takeda”) for w©♠☆∞orldwide rights to a precl≤φ®inical, peripherally-rest <ricted cannabinoid receptor 1 (CB1) monoclon✘φal antibody. Goldfinch § ₽≤Bio will assume all de ∞$velopment and commercialization±  responsibilities for the treatment of rare¥♣≥← and metabolic kidney dise•×ases worldwide. However, the agr&↑eement grants Takeda the option, α®∑prior to the initiation of pivotal studi≥≤↔±es, to request Goldfinch Bio negotiate with T♥♠ ÷akeda for sub-licensin"÷‌÷g of Japanese rights to Take ✘∑da. Financial terms of the agreement were not dis♦‌'♦closed. Goldfinch Bio plans to file an inve→‍stigational new drug (IND) applic₹​ ↕ation for this CB1 inhibitor, re-na↔ ​♣med GFB-024, in the second half of 2020.“In recen×♠•t years, our understandin₽δg of the role of CB1 signaling ∞α↕ in exacerbating progre♣•★←ssive kidney diseases has&↔  grown substantially. δ↕∑↑In this context, a monoclonalσ↓ antibody directed toward the CB1 receptor isσ→ potentially well-suited to elicit the beneficial≤™ pharmacology associated with the peripheral inhiα≤bition of the CB1 re✘β'ceptor,” said Anthony Johnson,πβ± M.D., President and Chief ©​↔'Executive Officer of Goldfinch Bio. “Goldfi☆∞nch Bio will deploy its biology platform and K‍↓idney Genome AtlasTM to ♠₽↔develop this therapeutic agent in s≥≈ubsets of patients with kidney disea£λΩ∑ses most likely to preferentially respond to CB1<☆₽ inhibition. With GFB-887, our TRPC5 inhibitor≤α≤× for FSGS, in Phase 1 clinical ¶→♥ development, this peri∏≈pheral CB1 inhibitor will be the™ ₽γ second clinic-ready program in Go÷‌‍ldfinch Bio’s pipeline. We look forward to coll♥★✔aborating with Takeda oε‌> n this program.”“Goldfinch Bio is ideally suit¶¶ed to advance development of ♠σthis program,” said Dan Cur​"∞ran, M.D., SVP and Head, Rare Diseases Tα&§£herapeutic Area Unit, Takeda. “The application of ¶ its precision medicine approach ​, from candidate target validation through​÷‍× to identification of pot✘"ential treatment-relevant s§∏↓ubgroups, is unique i↓≈± n the development of chronic metabolic kidney disΩ→☆ease treatments.”Precl↓"βφinical data support t ♥he inhibition of CB1 signaling as a novel treatme♥←nt of Diabetic Nephropathy (DN&↑γ) and obesity-related glomerulopathies (O₩∏RG), given the potential εσσmetabolic benefits an×₩φ£d direct effects on the kidney ₽φto prevent fibrosis and preser₹'₩ve kidney function. DN develops in 30 to←↔ 40 percent of patients who have diabetes and ←♥is a leading cause of morbidity, mortality ✘βand end-stage kidney disease in the Unit÷←♣ed States and worldw<₩ide. ORG is a rare kidney disorder ​→ characterized by signifi¶‌cant proteinuria and progress™♦★ive renal dysfunction. A®☆δ×lthough both DN and ORG are increasing in pr‍♠↑αevalence in parallel with the obesity epidem ₩₹§ic, well-established ¶×disease modifying therapies ar↔☆e lacking. Goldfinch Bio plans ≠π∞∏to initiate a phase 1 study for GFB-024 $εΩin 2H 2020.information&∑∏Ωnbsp;source:pharma focus Asia♥≤The original link:https://www.♠★pharmafocusasia.com/news/goldfinch-bio-announce'♦s-licensing-agreement-with-takeda-for-cb1-≈"​φmonoclonal-antibody-f ≠or-the-treatment-of-rare-and-me&$tabolic-kidney-diseases2019 Asia-pacif≥‍↔ic pharma IP Leader Summit: http:/$™</en.zenseegroup.com/p∑§/404716/ will be held in Beijing&nb✔¥≈sp; on November 14-15, and will→​λφ attract more than 500 industry experts∑↓σ from domestic and foreign pharmaceutical compa≈<→÷nies, biotechnology companies,≥∏∑ governments, associations, law f≠♦®irms, intellectual property¶→→" agents and other companies to atten∏&d.Official registration an×<♦Ωd consultation channels:Contact：AnnPhon©§e: 021-65650305Email：Marketing@zenseegr≤₩ oup.comhttp://en.zenseegro★§‌<up.com/p/510934/